Issue 3 AM

Anne Davidson, MBBS, FRACP, shared recent literature furthering the fundamental science of rheumatology, including the use of artificial intelligence in drug development, while Bryant England, MD, PhD, detailed new developments in clinical science that have been published in the past year, including Sjögren’s disease terminology.

Basia Belza, RN, PhD, opened the session with clinical highlights. She was joined by Marian Hannan, DSc, MPH, who focused on basic science, and Carol Oatis, PhD, PT, who discussed rehabilitation.

Michael Weinblatt, MD, will outline how past approaches, such as gold therapy in the 1930s, and the advanced biologics being used today have laid the groundwork for future rheumatoid arthritis therapies.

Five presentations will highlight practical interventions crafted by people living with rheumatic disease that can be applied in daily life by other patients. Session moderator Puja Khanna, MD, MPH, explains the importance of understanding patients’ lived experiences.

Edward Schwarz, PhD, will explore the cellular and molecular mechanisms that impact rheumatoid arthritis progression, including joint drainage, immune regulation, and chronic inflammation.

Rae Yeung, MD, PhD, and others from the Understanding Childhood Arthritis Network’s Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Diseases will outline new developments in juvenile idiopathic arthritis (JIA) facilitated by a team science approach to translational research.